SAN RAFAEL, Calif.—The Eye Institute, based here, recently announced that an informal nationwide survey of eye doctors and patients shows success with the use of a recently launched product, i-Lid Cleanser from NovaBay Pharmaceuticals, to treat evaporaive dry eye syndrome associated with blepharitis and meibomian gland dysfunction. The condition is the result of over-colonization of Staph bacteria, resulting in inflammation of eye lids and blockage of meibomian glands that help lubricate the eye surface.

“We’re finding this innovative product has had significant impact in helping many patients,” said Kathryn Najafi-Tagol, MD, founder and medical director of the Eye Institute.

i-Lid Cleanser has broad in-vitro antimicrobial activity and has been cleared by the FDA as a skin and wound cleanser. i-Lid Cleanser maintains its antimicrobial activity by the use of NovaBay’s proprietary ingredient, Neutrox, which contains the same active ingredient used by white blood cells as their first line of defense against bacteria and other microbial invaders. Lab tests show Neutrox not only kills bacteria, it also neutralizes the bacterial toxins that contribute to blepharitis and another condition called dry eye syndrome.